ATHROMBIN-K
Pre-Launchwarfarin potassium
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
ATHROMBIN-K (warfarin potassium) is 12.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATHROMBIN-K (warfarin potassium) is an oral anticoagulant that inhibits vitamin K-dependent clotting factor synthesis, indicated for thromboembolic disease prevention and treatment. It is a racemic mixture of R- and S-enantiomers, with the S-enantiomer exhibiting 2–5 times greater anticoagulant activity. Warfarin achieves anticoagulation within 24 hours, with peak effect at 72–96 hours and a therapeutic duration of 2–5 days per dose.
Pre-Launch
Pre-launch stage with minimal current commercial infrastructure; teams will likely focus on preparation activities, market access strategy, and launch readiness planning rather than operational scale.
Mechanism of Action
12.1 Mechanism of Action Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.